Long-Term Safety of Growth Hormone Deficiency Treatment in Cancer and Sellar Tumors Adult Survivors: Is There a Role of GH Therapy on the Neoplastic Risk?

被引：3
作者：
Di Somma, Carolina [1 ,2 ]
Scarano, Elisabetta [1 ]
Arianna, Rossana [1 ]
Romano, Fiammetta [1 ]
Lavorgna, Mariarosaria [1 ]
Serpico, Domenico [1 ]
Colao, Annamaria [1 ,2 ]
机构：
[1] Univ Naples Federico II, Dept Clin Med & Surg, Endocrinol Diabet & Androl Unit, I-80131 Naples, Italy
[2] Univ Naples Federico II, UNESCO Chair Educ Hlth & Sustainable Dev, I-80131 Naples, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 02期
关键词：
GH treatment; cancer risk; GHD; NONFUNCTIONING PITUITARY-ADENOMA; CHILDHOOD-CANCER; REPLACEMENT THERAPY; FACTOR-I; HYPOPITUITARY PATIENTS; SUBSEQUENT NEOPLASMS; 2ND NEOPLASMS; BRAIN-TUMORS; RADIATION-THERAPY; ENDOCRINE-SOCIETY;
D O I：
10.3390/jcm12020662
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Experimental studies support the hypothesis that GH/IGF-1 status may influence neoplastic tissue growth. Epidemiological studies suggest a link between GH/IGF-1 status and cancer risk. However, several studies regarding GH replacement safety in childhood cancer survivors do not show a prevalence excess of de novo cancers, and several reports on children and adults treated with GH have not shown an increase in observed cancer risk in these patients. The aim of this review is to provide an at-a-glance overview and the state of the art of long-term effects of GH replacement on neoplastic risk in adults with growth hormone deficiency who have survived cancer and sellar tumors.
引用
收藏
页数：15
相关论文
共 110 条
  • [1] Abdel R.O., EPIDEMIOLOGIC TRANSI
  • [2] GH replacement in 1034 growth hormone deficient hypopituitary adults:: demographic and clinical characteristics, dosing and safety
    Abs, R
    Bengtsson, BÅ
    Hernberg-Ståhl, E
    Monson, JP
    Tauber, JP
    Wilton, P
    Wüster, C
    [J]. CLINICAL ENDOCRINOLOGY, 1999, 50 (06) : 703 - 713
  • [3] Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis
    Abs, Roger
    Mattsson, Anders F.
    Thunander, Maria
    Verhelst, Johan
    Goth, Miklos I.
    Wilton, Patrick
    Koltowska-Haggstrom, Maria
    Luger, Anton
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (03) : 297 - 305
  • [4] Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis
    Alotaibi, Nawaf M.
    Noormohamed, Nadia
    Cote, David J.
    Alharthi, Salman
    Doucette, Joanne
    Zaidi, Hasan A.
    Mekary, Rania A.
    Smith, Timothy R.
    [J]. WORLD NEUROSURGERY, 2018, 109 : 487 - +
  • [5] Bray Freddie, 2018, CA Cancer J Clin, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
  • [6] Occurrence of Multiple Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
    Armstrong, Gregory T.
    Liu, Wei
    Leisenring, Wendy
    Yasui, Yutaka
    Hammond, Sue
    Bhatia, Smita
    Neglia, Joseph P.
    Stovall, Marilyn
    Srivastava, Deokumar
    Robison, Leslie L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3056 - 3064
  • [7] GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence
    Arnold, J. R.
    Arnold, D. F.
    Marland, A.
    Karavitaki, N.
    Wass, J. A. H.
    [J]. CLINICAL ENDOCRINOLOGY, 2009, 70 (03) : 435 - 438
  • [8] GROWTH-HORMONE THERAPY AND TUMOR RECURRENCE - FINDINGS IN CHILDREN WITH BRAIN NEOPLASMS AND HYPOPITUITARISM
    ARSLANIAN, SA
    BECKER, DJ
    LEE, PA
    DRASH, AL
    FOLEY, TP
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1985, 139 (04): : 347 - 350
  • [9] Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood?
    Auer, Matthias K.
    Stieg, Mareike R.
    Hoffmann, Janis
    Stalla, Guenter K.
    [J]. CLINICAL ENDOCRINOLOGY, 2016, 84 (06) : 862 - 869
  • [10] Consequences of growth hormone (GH) overexpression and GH resistance
    Bartke, A
    Chandrashekar, V
    Bailey, B
    Zaczek, D
    Turyn, D
    [J]. NEUROPEPTIDES, 2002, 36 (2-3) : 201 - 208
12345678910